Cargando…

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer

A cost–utility analysis was performed based on the Rethinking Clinical Trials (REaCT) bone-targeted agents (BTA) clinical trial that compared 12-weekly (once every 12 weeks) (n = 130) versus 4-weekly (once every 4 weeks) (n = 133) BTA dosing for metastatic breast and castration-resistant prostate (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Megan M., Clemons, Mark, Stober, Carol, Jeong, Ahwon, Vandermeer, Lisa, Mates, Mihaela, Blanchette, Phillip, Joy, Anil Abraham, Aseyev, Olexiy, Pond, Gregory, Fergusson, Dean, Ng, Terry L., Thavorn, Kednapa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161812/
https://www.ncbi.nlm.nih.gov/pubmed/34068083
http://dx.doi.org/10.3390/curroncol28030171
_version_ 1783700581778456576
author Tu, Megan M.
Clemons, Mark
Stober, Carol
Jeong, Ahwon
Vandermeer, Lisa
Mates, Mihaela
Blanchette, Phillip
Joy, Anil Abraham
Aseyev, Olexiy
Pond, Gregory
Fergusson, Dean
Ng, Terry L.
Thavorn, Kednapa
author_facet Tu, Megan M.
Clemons, Mark
Stober, Carol
Jeong, Ahwon
Vandermeer, Lisa
Mates, Mihaela
Blanchette, Phillip
Joy, Anil Abraham
Aseyev, Olexiy
Pond, Gregory
Fergusson, Dean
Ng, Terry L.
Thavorn, Kednapa
author_sort Tu, Megan M.
collection PubMed
description A cost–utility analysis was performed based on the Rethinking Clinical Trials (REaCT) bone-targeted agents (BTA) clinical trial that compared 12-weekly (once every 12 weeks) (n = 130) versus 4-weekly (once every 4 weeks) (n = 133) BTA dosing for metastatic breast and castration-resistant prostate (CRPC) cancer. Using a decision tree model, we calculated treatment and symptomatic skeletal event (SSE) costs as well as quality-adjusted life-years (QALYs) for each treatment option. Deterministic and probabilistic sensitivity analyses were performed to assess the robustness of the study findings. The total cost of BTA treatment in Canadian dollars (C$) and estimated QALYs was C$8965.03 and 0.605 QALY in the 4-weekly group versus C$5669.95 and 0.612 QALY in the 12-weekly group, respectively. De-escalation from 4-weekly to 12-weekly BTA reduces cost (C$3293.75) and improves QALYs by 0.008 unit, suggesting that 12-weekly BTA dominates 4-weekly BTA in breast and CRPC patients with bone metastases. Sensitivity analysis suggests high levels of uncertainty in the cost-effectiveness findings. De-escalation of bone-targeted agents is cost-effective from the Canadian public payer’s perspective.
format Online
Article
Text
id pubmed-8161812
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81618122021-05-29 Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer Tu, Megan M. Clemons, Mark Stober, Carol Jeong, Ahwon Vandermeer, Lisa Mates, Mihaela Blanchette, Phillip Joy, Anil Abraham Aseyev, Olexiy Pond, Gregory Fergusson, Dean Ng, Terry L. Thavorn, Kednapa Curr Oncol Article A cost–utility analysis was performed based on the Rethinking Clinical Trials (REaCT) bone-targeted agents (BTA) clinical trial that compared 12-weekly (once every 12 weeks) (n = 130) versus 4-weekly (once every 4 weeks) (n = 133) BTA dosing for metastatic breast and castration-resistant prostate (CRPC) cancer. Using a decision tree model, we calculated treatment and symptomatic skeletal event (SSE) costs as well as quality-adjusted life-years (QALYs) for each treatment option. Deterministic and probabilistic sensitivity analyses were performed to assess the robustness of the study findings. The total cost of BTA treatment in Canadian dollars (C$) and estimated QALYs was C$8965.03 and 0.605 QALY in the 4-weekly group versus C$5669.95 and 0.612 QALY in the 12-weekly group, respectively. De-escalation from 4-weekly to 12-weekly BTA reduces cost (C$3293.75) and improves QALYs by 0.008 unit, suggesting that 12-weekly BTA dominates 4-weekly BTA in breast and CRPC patients with bone metastases. Sensitivity analysis suggests high levels of uncertainty in the cost-effectiveness findings. De-escalation of bone-targeted agents is cost-effective from the Canadian public payer’s perspective. MDPI 2021-05-13 /pmc/articles/PMC8161812/ /pubmed/34068083 http://dx.doi.org/10.3390/curroncol28030171 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tu, Megan M.
Clemons, Mark
Stober, Carol
Jeong, Ahwon
Vandermeer, Lisa
Mates, Mihaela
Blanchette, Phillip
Joy, Anil Abraham
Aseyev, Olexiy
Pond, Gregory
Fergusson, Dean
Ng, Terry L.
Thavorn, Kednapa
Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
title Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
title_full Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
title_fullStr Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
title_full_unstemmed Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
title_short Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
title_sort cost-effectiveness analysis of 12-versus 4-weekly administration of bone-targeted agents in patients with bone metastases from breast and castration-resistant prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161812/
https://www.ncbi.nlm.nih.gov/pubmed/34068083
http://dx.doi.org/10.3390/curroncol28030171
work_keys_str_mv AT tumeganm costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer
AT clemonsmark costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer
AT stobercarol costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer
AT jeongahwon costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer
AT vandermeerlisa costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer
AT matesmihaela costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer
AT blanchettephillip costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer
AT joyanilabraham costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer
AT aseyevolexiy costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer
AT pondgregory costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer
AT fergussondean costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer
AT ngterryl costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer
AT thavornkednapa costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer